Colorectal cancer (CRC) is the main cause of global cancer death, accounting for 9.2%of the total global cancer death in 2018. Removal adenoma polyps can greatly reduce the incidence and mortality of the CRC. A large amount of evidence shows that non -steroidal anti -inflammatory drugs (NSAIDS), especially aspirin, can reduce the risk of colorectal adenoma and cancer. However, given potential drug adverse reactions, such as gastrointestinal bleeding/ulcers and cardiovascular incidents, it is especially important for patients who are treated to determine their benefits than risks. This study aims to discuss whether this association has risk differences due to the gene polymorphism of CRC.
German researchers conducted a large CRC case -control study. Use 140 CRC -related risk sites (PRS) to quantify genetic risks. Using multi -variable logic regression models to analyze NSAIDS (≥ 2 times a week, at least 1 year) in the entire population and Asian group. The influence of NSAIDS on CRC risk compares the “genetic risk equivalent” (GRE).
A total of 5129 CRC cases and 4093 patients were included in this study. The research results show that regular use of non-steroidal anti-inflammatory drugs (including aspirin) and CRC risk reduction [(or) 0.66, 95% (CI) 0.59, 0.74], only regularly use Aspirin (OR 0.73, 95% CI 0.65-0.83 ) It can also play a role in reducing the risk of CRC. The research results show that the drugs have no signs of interaction with PRS. The effect of using NSAID is equivalent to a 32 percentage point of PRS (GRE -32, 95% CI -41, -22).
This study has confirmed that regardless of individual genetic characteristics, the use of NSAID is often related to CRC risk.
Xuechen Chen. Et Al. Non-techneidal anti-inflammatic drags, Polygenic Risk SCORE and Colorectal Cancer Risk.